On December 10th, Merck announced that its PD-1 inhibitor pembrolizumab (trade name: Kelida®) Approved by the National Medical Products Administration, the combination of radiotherapy and chemotherapy is used for the treatment of stage III-IVA cervical cancer patients in the International Federation of Obstetrics and Gynecology (FIGO) 2014. The approval of this new indication is based on data from the global phase III clinical trial KEYNOTE-A18.
At the same time, the company announced its antifungal drug, NozoNobel& reg; The new indications for two dosage forms, Bosaconazole enteric coated tablets and Bosaconazole injection, have been approved by the Drug Evaluation Center of the National Medical Products Administration. The prevention and treatment population has been expanded to include pediatric patients, providing a safe and effective new treatment option for antifungal prevention and treatment in pediatric patients.
At present, Novartis&Co; reg; There are three dosage forms approved in China, including posaconazole oral suspension, posaconazole enteric coated tablets, and posaconazole injection. All three dosage forms have been included in the National Basic Medical Insurance, Work Injury Insurance, and Maternity Insurance Drug Catalogue (2023).